New combo therapy tested for hard-to-treat colorectal cancer
NCT ID NCT02613650
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested a combination of two drugs (MEK162 and mFOLFIRI) in 25 adults with advanced RAS-positive colorectal cancer that had stopped responding to standard treatment. The main goal was to find the safest dose and check for side effects. Researchers also looked at whether tumors shrank or stayed stable.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED KRAS POSITIVE METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Huntsman Cancer Institute
Salt Lake City, Utah, 84112, United States